Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)

Abrams Paul; Kelleher Con; Staskin David; Rechberger Tomasz; Kay Richard; Martina Reynaldo; Newgreen Donald; Paireddy Asha; van Maanen Rob; Ridder Arwin

首页> 外文期刊>European urology >Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)

【24h】

Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)

机译：Mirabegron和Solifenacin联合治疗膀胱过度活动症患者的疗效和安全性来自一项随机，双盲，剂量范围第二阶段研究（Symphony）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Combining the beta 3-adrenoceptor agonist mirabegron and the antimuscarinic (AM) agent solifenacin may improve efficacy in the treatment of overactive bladder (OAB) while reducing the AM side effects.

机译：背景：将β3-肾上腺素能受体激动剂米拉贝隆与抗毒蕈碱（AM）药物索非那新合用可能会改善膀胱过度活动症（OAB）的治疗效果，同时减少AM副作用。

著录项

来源
《European urology》 |2015年第3期|共12页
作者
Abrams Paul; Kelleher Con; Staskin David; Rechberger Tomasz; Kay Richard; Martina Reynaldo; Newgreen Donald; Paireddy Asha; van Maanen Rob; Ridder Arwin;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词
Combination therapy; Mirabegron; Overactive bladder; Solifenacin;

机译：联合治疗;米拉贝隆;膀胱过度活动症;索非那新;

相似文献

外文文献
中文文献
专利

1. Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony) [J] . Abrams Paul, Kelleher Con, Staskin David, European urology . 2015,第3期

机译：Mirabegron和Solifenacin联合治疗膀胱过度活动症患者的疗效和安全性来自一项随机，双盲，剂量范围第二阶段研究（Symphony）
2. Re: Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-Blind, Dose-Ranging, Phase 2 Study (Symphony) [J] . Wein Alan J. The Journal of Urology . 2015,第1期

机译：回复：Mirabegron和索非那新联合治疗膀胱过度活动症患者：一项随机，双盲，剂量范围，2期研究（Symphony）的疗效和安全性结果
3. Re: Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony) [J] . Cruz Francisco European urology . 2015,第6期

机译：Re：用Mirabegron和Solifenacin的过度活性膀胱患者组合治疗：随机，双盲，剂量 - 测量，第2期研究（Symphony）的疗效和安全结果
4. Electrical Stimulation of the Transcutaneous Posterior Tibial Nerve for the Treatment of Patients with Detrusor Overactivity Due to Neurogenic Hiperactive Bladder in Multiple Sclerosis A Case Study [C] . Fabiana S. B. Perez, Luciana R. Tenorio Peixoto, Fabiano Soares, International Conference on Biomedical Electronics and Devices . 2014

机译：经皮后胫骨神经的电气刺激治疗多发性硬化中神经源性膀胱患者患者的患者案例研究
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority randomized phase IIIb trial [O] . Jose E. Batista, Heinz Kölbl, Sender Herschorn, 2015

机译：米拉贝隆与索非那新相比因缺乏疗效而对先前过度抗毒蕈碱治疗不满意的膀胱过度活动症患者的疗效和安全性：一项非劣效性随机IIIb期临床试验的结果
7. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy:A Randomised, Double-blind, Multicentre, Phase 3b Study (BESIDE) [O] . Drake Marcus, Chapple Christopher, Esen Ahmet, 2016

机译：对于开始4周Solifenacin单药治疗反应不佳的失禁性膀胱过度活动症患者，Mirabegron联合Solifenacin疗法的疗效和安全性：一项随机，双盲，多中心，3b期研究（BESIDE）

Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)

摘要

著录项

相似文献

相关主题

期刊订阅